StreetInsider.com News Articles

Oppenheimer Reiterates Outperform Rating on Coherus Biosciences (CHRS): "buying opportunity ahead of key catalysts"

Tue, 10 Mar 2026 08:15:15 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $10.00 price target on Coherus Biosciences (NASDAQ: CHRS)

The analyst commented, "CHRS is now trading flat (vs. flat XBI) despite earlier weakness immediately following 4Q25 earnings, as we predict the market has become increasingly appreciative of the pipeline opportunity given key readouts in 2026, despite FY25 Loqtorzi sales falling slightly short of consensus ($40.8M vs. $43.4M, respectively). That said, we remain optimistic for Loqtorzi growth going forward considering that small NPC epidemiology renders Loqtorzi highly promotionally sensitive, which CHRS plans to leverage with investment in commercial infrastructure this year. Near term, focus

Form 10-K Coherus Oncology, Inc. For: Dec 31

Mon, 09 Mar 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260309/26133088.html

Form 10-K Coherus Oncology, Inc. For: Dec 31

Mon, 09 Mar 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260309/26133088.html

Form 8-K Coherus Oncology, Inc. For: Mar 09

Mon, 09 Mar 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260309/26132842.html

Form 8-K Coherus Oncology, Inc. For: Mar 09

Mon, 09 Mar 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260309/26132842.html

Coherus BioSciences (CHRS) Reports In-Line Q4 EPS

Mon, 09 Mar 2026 16:24:43 -0400

Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.34), in-line with the analyst estimate of ($0.34). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $14.16 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Mon, 09 Mar 2026 16:15:00 -0400

– LOQTORZI^® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –

– Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 –

– $172.1 million in year ending cash, cash equivalents and marketable securities –

– Conference call today at 4:30 p.m. Eastern Standard Time –

REDWOOD CITY, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Mon, 09 Mar 2026 16:15:00 -0400

– LOQTORZI^® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –

– Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 –

– $172.1 million in year ending cash, cash equivalents and marketable securities –

– Conference call today at 4:30 p.m. Eastern Standard Time –

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Mon, 02 Mar 2026 09:30:00 -0400

REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, March 9, 2026, starting

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Mon, 02 Mar 2026 09:30:00 -0400

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, March 9, 2026, starting

Coherus Oncology to Participate in Upcoming Investor Conferences

Mon, 23 Feb 2026 09:30:00 -0400

REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus Oncology website: https://investors.coherus.com/events-presentations. A replay of the presentation will be available on this same website for approximately 90 days.

46^th Annual TD Cowen Healthcare Conference in Boston, on Wednesday, March 4, 2026, at 11:50 a.m. Eastern Daylight Time
Citizens Life Sciences Conference in Miami, on Tuesday, March 10,

Coherus Oncology to Participate in Upcoming Investor Conferences

Mon, 23 Feb 2026 09:30:00 -0400

46^th Annual TD Cowen Healthcare Conference in Boston, on Wednesday, March 4, 2026, at 11:50 a.m. Eastern Daylight Time
Citizens Life Sciences Conference in Miami, on Tuesday, March 10,

Coherus Oncology completes $50.1 million stock offering